Korsana Biosciences, Inc.

KRSA Nasdaq SEC CIK 1755237
Follow Korsana Biosciences Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$46.4M −113.7% vs same quarter last year
EPS, diluted −$3.19 +91.9% vs same quarter last year
Operating cash flow −$46.8M −353.4% vs same quarter last year
Operating income −$48.3K −119.9% vs same quarter last year
Revenue by quarter
$1.8M
$81K
$93K
$875K
$1M
$0
$0
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income9 fiscal years
  • Revenue
  • Net income
−$150M−$100M−$50M$0$50MFY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$2.1M−$3.5M
FY24$2M−$3.1M
FY23$0−$5.3M
FY22$297K−$44.1M
FY21$3.9M−$51.6M
FY20$2.3M−$77.8M
FY19$4.5M−$123M
FY18-−$115.3M
FY17--
MarginsShare of revenue
  • Operating margin
  • Net margin
−15000%−10000%−5000%0%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−239.8%−170.1%
FY24−181.4%−152.8%
FY23--
FY22−6242.4%−14841.1%
FY21−1400.2%−1310.2%
FY20−3539.4%−3388.6%
FY19−2774.3%−2729.3%
FY18--
FY17--
Free cash flowOperating cash flow minus capital expenditure
−$150M−$100M−$50M$0FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25-
FY24-
FY23-
FY22−$40.6M
FY21−$36.5M
FY20−$74M
FY19−$109.1M
FY18−$100.9M
FY17-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Korsana Biosciences
  • Healthcare median
−15000%−10000%−5000%0%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearKorsana BiosciencesHealthcare median
FY25−170.1%−30.6%
FY24−152.8%−47%
FY23-−58%
FY22−14841.1%−80.4%
FY21−1310.2%−71.8%
FY20−3388.6%−62.2%
FY19−2729.3%−46.2%
FY18-−49.6%
FY17-−45.9%